Company / Return on Equity (ROE)
AbCellera Biologics Inc. Return on Equity (ROE) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-15.1%
FY2025
5-year range
-21.6% / 14.3%
FY2021-FY2025
Trend
+1.8%
vs FY2024
Sector context
#69 of 190
Health Care
What the data says
AbCellera Biologics Inc. reports negative total equity of -15.1% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-15.1% in FY2025 with a 5-year CAGR of -29.5%.
Declined from -12.7% to -15.1% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -29.5pp
- 5-Year Change
- -29.5pp
- 10-Year Change
- -
Sector benchmark
#69 of 190 in Health CareTop 36% of 190This company -15.1% Sector average -50.4%
▼
+70.0% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 1.8% year-over-year.
- Currently 35.3pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2022.
- Lowest return on equity (roe) in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -15.1% | +1.8% |
| FY2024 | -15.4% | -21.4% |
| FY2023 | -12.7% | -188.7% |
| FY2022 | 14.3% | +166.4% |
| FY2021 | -21.6% | -250.6% |
| FY2020 | 14.3% | +166.4% |
| FY2019 | -21.6% | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026